Market Overview:
The global systemic lupus erythematosus (SLE) medication market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The market growth is attributed to the increasing prevalence of SLE, rising awareness about SLE and its treatment options, and technological advancements in the field of SLE medications. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. Based on type, corticosteroids are estimated to account for the largest share in 2018 and are projected to maintain their dominance during the forecast period. This can be attributed to their wide use for treating various symptoms associated with SLE such as inflammation and pain. Non-steroidal anti-inflammatory drugs (NSAIDs) are also estimated to account for a significant share in this market owing their ability reduce inflammation without causing any serious side effects. Based on application, intravenous administration accounted for majority share in 2017 and is projected dominate during forecast period due its ease if use an preference by physicians owing better patient compliance rates as compared oral administration routes .
 Medication Industry Outlook.svg)
Product Definition:
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect any organ in the body. The immune system attacks healthy cells and tissues, which can cause inflammation, pain, and damage. SLE Medication is important because it helps to suppress the immune system and prevent further damage to organs.
Corticosteroids:
Lupus Erythematosus or Systemic Lupus Erythematosus (SLE) is a chronic, progressive, and incurable autoimmune disorder of the skin, joints and/or gastrointestinal system. It affects women more than men. The disease has three different forms namely; early lupus (EL), late lupus (LL), and systemic lupus erythematosous (SLE).
Non-Steroidal Anti-inflammatory Drugs (NSAIDs):
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used medications for the treatment of pain, inflammation and fever. They work by blocking some of the body's own natural inflammatory substances called prostaglandins. As a result, NSAIDs reduce swelling and redness associated with acute injuries as well as chronic diseases such as rheumatoid arthritis and cancer.
Application Insights:
On the basis of application, the global SLE medication market is segmented into intravenous, oral, topical and others. The intravenous segment dominated the overall market in terms of revenue in 2017 owing to high usage rates for various indications such as renal failure and cancer. In addition, a large number of product launches by different companies are expected to drive growth during the forecast period. For instance, in January 2018 Pfizer Inc launched its Prescrition Lyopred Intravenous Immunoglobulin (IVIG) therapy for patients suffering from moderate-to-severe SLE who require Plasmapheresis therapy or need a second line treatment option.
The oral segment is anticipated to witness significant growth over the forecast period due largely to increasing usage rates for various indications such as rheumatoid arthritis and lupus nephritis among others. Moreover, new product launches coupled with growing awareness about effective treatment options are likely to boost industry growth during this study period.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, high adoption rate of modern therapeutics, and favorable reimbursement policies are some factors contributing to its growth. In addition, the prevalence of SLE is comparatively higher in North America than other regions which is fueling the demand for systemic lupus erythematosus medication globally.
Asia Pacific region is expected to witness lucrative growth over the forecast period owing to increasing disposable income and healthcare expenditure levels coupled with rising awareness about available treatment options among patients suffering from chronic diseases such as Systemic Lupus Erythematosus (SLE). Moreover, growing penetration of major pharmaceutical companies due to low manufacturing cost will also drive this market further. Rising incidence rates & prevalence along with an increase in patient pool that require long term & continuous treatment are driving this regional market further making it one of the fastest-growing markets globally by 2030 time span.
Growth Factors:
- Increasing incidence of SLE
- Growing awareness about SLE and its treatment options
- Rising demand for better and more effective medications for the treatment of SLE
- Availability of government funding for research on new lupus medications
- Technological advancements in the field of lupus medication development
Scope Of The Report
Report Attributes
Report Details
Report Title
Systemic Lupus Erythematosus (SLE) Medication Market Research Report
By Type
Corticosteroids, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Anti-Inflammatories, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Antimalarials, BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS), Immunosuppressive Agents/Immune Modulators, Anticoagulants
By Application
Intravenous, Oral, Topical, Others
By Companies
GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, MedImmune, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
227
Number of Tables & Figures
159
Customization Available
Yes, the report can be customized as per your need.
Global Systemic Lupus Erythematosus (SLE) Medication Market Report Segments:
The global Systemic Lupus Erythematosus (SLE) Medication market is segmented on the basis of:
Types
Corticosteroids, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Anti-Inflammatories, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Antimalarials, BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS), Immunosuppressive Agents/Immune Modulators, Anticoagulants
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Intravenous, Oral, Topical, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- ImmuPharma
- Merck Serono
- UCB
- Amgen
- HGS
- Immunomedics
- MedImmune
- Sanofi
 Medication Market Overview.svg)
Highlights of The Systemic Lupus Erythematosus (SLE) Medication Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Corticosteroids
- Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- Anti-Inflammatories
- Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
- Antimalarials
- BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)
- Immunosuppressive Agents/Immune Modulators
- Anticoagulants
- By Application:
- Intravenous
- Oral
- Topical
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Systemic Lupus Erythematosus (SLE) Medication Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Medication Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects the skin, joints, and other organs. The most common medications used to treat SLE are corticosteroids (such as prednisone), immunosuppressants (such as azathioprine or cyclophosphamide), and antimalarials (such as hydroxychloroquine).
Some of the major companies in the systemic lupus erythematosus (sle) medication market are GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, MedImmune, Sanofi.
The systemic lupus erythematosus (sle) medication market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Systemic Lupus Erythematosus (SLE) Medication Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Systemic Lupus Erythematosus (SLE) Medication Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Systemic Lupus Erythematosus (SLE) Medication Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Systemic Lupus Erythematosus (SLE) Medication Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Systemic Lupus Erythematosus (SLE) Medication Market Size & Forecast, 2020-2028
4.5.1 Systemic Lupus Erythematosus (SLE) Medication Market Size and Y-o-Y Growth
4.5.2 Systemic Lupus Erythematosus (SLE) Medication Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Corticosteroids
5.2.2 Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
5.2.3 Anti-Inflammatories
5.2.4 Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
5.2.5 Antimalarials
5.2.6 BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)
5.2.7 Immunosuppressive Agents/Immune Modulators
5.2.8 Anticoagulants
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Intravenous
6.2.2 Oral
6.2.3 Topical
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Systemic Lupus Erythematosus (SLE) Medication Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Systemic Lupus Erythematosus (SLE) Medication Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Corticosteroids
9.6.2 Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
9.6.3 Anti-Inflammatories
9.6.4 Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
9.6.5 Antimalarials
9.6.6 BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)
9.6.7 Immunosuppressive Agents/Immune Modulators
9.6.8 Anticoagulants
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Intravenous
9.10.2 Oral
9.10.3 Topical
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Corticosteroids
10.6.2 Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
10.6.3 Anti-Inflammatories
10.6.4 Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
10.6.5 Antimalarials
10.6.6 BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)
10.6.7 Immunosuppressive Agents/Immune Modulators
10.6.8 Anticoagulants
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Intravenous
10.10.2 Oral
10.10.3 Topical
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Corticosteroids
11.6.2 Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
11.6.3 Anti-Inflammatories
11.6.4 Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
11.6.5 Antimalarials
11.6.6 BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)
11.6.7 Immunosuppressive Agents/Immune Modulators
11.6.8 Anticoagulants
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Intravenous
11.10.2 Oral
11.10.3 Topical
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Corticosteroids
12.6.2 Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
12.6.3 Anti-Inflammatories
12.6.4 Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
12.6.5 Antimalarials
12.6.6 BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)
12.6.7 Immunosuppressive Agents/Immune Modulators
12.6.8 Anticoagulants
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Intravenous
12.10.2 Oral
12.10.3 Topical
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Corticosteroids
13.6.2 Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
13.6.3 Anti-Inflammatories
13.6.4 Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
13.6.5 Antimalarials
13.6.6 BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)
13.6.7 Immunosuppressive Agents/Immune Modulators
13.6.8 Anticoagulants
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Intravenous
13.10.2 Oral
13.10.3 Topical
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Systemic Lupus Erythematosus (SLE) Medication Market: Competitive Dashboard
14.2 Global Systemic Lupus Erythematosus (SLE) Medication Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GSK
14.3.2 ImmuPharma
14.3.3 Merck Serono
14.3.4 UCB
14.3.5 Amgen
14.3.6 HGS
14.3.7 Immunomedics
14.3.8 MedImmune
14.3.9 Sanofi
